Eton Pharmaceuticals secures U.S. commercialization rights to IMPAVIDO® for $4.25M fixed fees

Eton Pharmaceuticals, Inc.

• Eton will pay $4.25M in fixed fees ($125k Jul 2026, then $1.25M Apr 2027, etc.) plus up to $4M in milestone payments based on cumulative net sales.
• Royalty rates: 55% of net sales up to $7M/year, 50% above $7M/year; Supplier covers product costs and regulatory, Eton covers sales and marketing.
• Exclusive U.S. commercialization rights start September 26, 2026; IMPAVIDO® had 2025 U.S. sales of $8.1M (Symphony Health).
• IMPAVIDO® is the first FDA-approved oral therapy for leishmaniasis (visceral, cutaneous, mucosal), a rare parasitic disease.
• This expands Eton's rare disease portfolio to eleven commercial products (including ten prior).